LSK9985

LSK9985 is an investigational small molecule inhibitor that selectively targets Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). Developed by Elevar Therapeutics (formerly LSK BioPharma) and its parent company HLB, LSK9985 is designed as a potent anti-angiogenic agent for the treatment of solid tumors. By inhibiting VEGFR2, the drug disrupts the signaling pathways essential for the formation of new blood vessels (angiogenesis) within the tumor microenvironment, thereby starving the tumor of nutrients and oxygen. LSK9985 is characterized by its high selectivity for VEGFR2 compared to other kinases, potentially offering a more targeted therapeutic profile with reduced off-target effects. As of recent reports, the compound is in the preclinical stage of development, with ongoing research aimed at evaluating its efficacy and safety for various oncological indications.